Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 5Plasma cell 2Other hematologic neoplasm 2Lymphoid 2Genitourinary 2Thoracic 1Myeloid 1Gastrointestinal 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Leukemia 43Recurrence 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Non-Hodgkin 21Hematologic Neoplasms 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid 11Neoplasm, Residual 10Myeloproliferative Disorders 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Multiple Myeloma 9Lymphoma, Mantle-Cell 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Chromosome 17 deletion 6Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia, B-Cell 5Burkitt Lymphoma 5Primary Myelofibrosis 4GATA2 Deficiency 4Blast Crisis 4

Interventions

Cyclophosphamide 7Therapeutics 6Flow Cytometry 6Radiotherapy 4Peripheral Blood Stem Cell Transplantation 4Filgrastim 4Psychiatric Rehabilitation 3Polymerase Chain Reaction 3Paclitaxel 3Immunologic Techniques 3Immunoenzyme Techniques 3Doxorubicin 3Carboplatin 3Amplified Fragment Length Polymorphism Analysis 3venetoclax 2trametinib 2temsirolimus 2sargramostim 2ruxolitinib 2pertuzumab 2pembrolizumab 2palbociclib 2liposomal doxorubicin 2liposomal amphotericin B 2dabrafenib 2copanlisib 2bosutinib 2aldesleukin 2abiraterone 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × venetoclax × Other hematologic neoplasm × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02391480 2019-11-29

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

AbbVie

Phase 1 Completed
128 enrolled
BreastGenitourinaryLymphoidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Prostatic Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡